Keeping Track: Gavreto, Sogroya Bring Annual CDER Novel Approvals To 40; New Analgesic Products Make It Past US FDA
Executive Summary
The latest drug approval news and highlights from the Pink Sheet’s US FDA Performance Tracker.
You may also be interested in...
Finance Watch: Biopharma VC Funding Dips In Q3, Remains Relatively High For Year
Private Company Edition: Third quarter venture capital funding for biopharmaceutical firms fell from Q2, but activity remains near all-time highs year-to-date. Several companies announced VC financings in early October, including Ascidian, which launched with $50m in series A financing.
Novo’s Sogroya Impresses In Children With Convenience Advantage Over SOC
The Danish firm’s injectable growth hormone analogue has succeeded in a late-stage study of children with a growth disorder and offers more convenient dosing that could improve adherence.
Outpatient Care, Self-Insured Employers Drive Growth Of Non-Opioid Pain Meds
Opioids are cheap, but the economics of clinical practice, including the shift of care from inside the hospital to outpatient or ambulatory facilities, are creating new opportunities for Pacira BioSciences’ non-opioid treatments for pain. Improved reimbursement and increased usage among anesthesiologists are the biggest revenue drivers for the company’s two marketed products.